Vial Size |
25 mg , 50 mg |
---|
Avanafil (≥98%) - 50 mg vial
EGP3,420.00 / vial
Besifloxacin (≥98%) – 10 mg vial
EGP2,850.00
Linagliptin (≥98%)
EGP2,394.00 – EGP4,332.00 / vial
Product Name | Linagliptin analytical standard |
Synonym | Tradjenta, B1 1356BS, 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione |
Product Nawah code | AMAH21124 |
CAS number | 668270-12-0 |
Empirical Formula | C25H28N8O2 |
Molecular weight | 472.54g/mol |
PubChem Substance ID | 10096344 |
Storage temperature | 2-8 oC , Dark |
Physical appearance | White powder |
Purity | ≥98% |
Description | Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise |
Related literature | DrugBank: URL: https://www.drugbank.ca/drugs/DB08882
|
SKU:
N/A
Categories: Analytical Standards, API
Tags: 2ry standards, Analytical Standards, Certified Refrence Materials, Impurity, Linagliptin, pharmaceutical analytical testing, Working Standards
Additional information
Be the first to review “Linagliptin (≥98%)” Cancel reply
Reviews
There are no reviews yet.